OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Summary by AI BETAClose X

OKYO Pharma has appointed Flavio Mantelli, MD, PhD as Chief Medical Officer, leveraging his experience in leading the successful clinical development and FDA approval of Oxervate®, a blockbuster orphan therapy with over $1 billion in sales in 2024. Dr. Mantelli will spearhead the clinical and regulatory strategy for urcosimod in neuropathic corneal pain, building on its FDA Fast Track designation. This appointment, following the recent CEO hire, significantly strengthens OKYO's ophthalmology leadership team as they prepare to initiate a ~150 subject Phase 2b/3 study of urcosimod in the first half of the year.

Disclaimer*

UK 100

Latest directors dealings